Search Results - "de Jong, Pascal Hendrik Pieter"

Response to: 'Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis' by Garcia et al by van Mulligen, Elise, de Jong, Pascal Hendrik Pieter

Get more information

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial by van Mulligen, Elise, Weel, Angelique E, Hazes, J M, van der Helm-van Mil, Annette, de Jong, Pascal Hendrik Pieter

“…To evaluate the 2-year clinical effectiveness of two gradual tapering strategies. The first strategy consisted of tapering the conventional synthetic…”
Get more information

Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time? by van Ouwerkerk, Lotte, Verschueren, Patrick, Boers, Maarten, Emery, Paul, de Jong, Pascal Hendrik Pieter, Landewé, Robert Bm, Lems, Willem, Smolen, Josef S, Huizinga, Tom Wj, Allaart, Cornelia F, Bergstra, Sytske Anne

“…To compare the use of glucocorticoids (GC) over time in patients with rheumatoid arthritis (RA) who were or were not treated initially with GC bridging…”
Get more information

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study by van Mulligen, Elise, de Jong, Pascal Hendrik Pieter, Kuijper, Tjallingius Martijn, van der Ven, Myrthe, Appels, Cathelijne, Bijkerk, Casper, Harbers, Joop B, de Man, Yael, Molenaar, T H Esmeralda, Tchetverikov, Ilja, Goekoop-Ruiterman, Yvonne P M, van Zeben, Jende, Hazes, Johanna M W, Weel, Angelique E A M, Luime, Jolanda J

“…The aim of this study is to evaluate the effectiveness of two tapering strategies after achieving controlled disease in patients with rheumatoid arthritis…”
Get more information

Meta‐Analyses on the Effects of Disease‐Modifying Antirheumatic Drugs on the Most Relevant Patient‐Reported Outcome Domains in Rheumatoid Arthritis by Dikkenberg, Marijke, Luurssen‐Masurel, Nathalie, Kuijper, Tjallingius Martijn, Kok, Marc‐Redwart, Hazes, Johanna Maria Wilhelmina, Jong, Pascal Hendrik Pieter, Lopes‐Barreto, Deirisa, Weel‐Koenders, Angelique Elisabeth Adriana Maria

“…Objective Whereas in the treatment of rheumatoid arthritis much evidence exists on the effects of current pharmacologic treatment on clinical outcomes, little…”
Get full text

Possibilities for personalised medicine in rheumatoid arthritis: hype or hope by Heutz, Judith, de Jong, Pascal Hendrik Pieter

“…Knowledge of pathophysiology of rheumatoid arthritis (RA) has improved over the past decades, which resulted in new treatment options and strategies that led…”
Get full text

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial by van Mulligen, Elise, Weel, Angelique E, Kuijper, Tjallingius Martijn, Denissen, N H A M, Gerards, Andreas H, de Jager, Mike H, Lam-Tse, Wai-Kwan, Hazes, J M, van der Helm-van Mil, Annette, de Jong, Pascal Hendrik Pieter, Luime, Jolanda J

“…The aim of the current study was to evaluate the 2-year cost-utility ratio between tapering conventional synthetic disease-modifying antirheumatic drugs…”
Get more information

The impact of different (rheumatoid) arthritis phenotypes on patients’ lives by Luurssen-Masurel, Nathalie, Weel, Angelique Elisabeth Adriana Maria, Hazes, Johanna Maria Wilhelmina, de Jong, Pascal Hendrik Pieter

“…Abstract Objectives To compare patient-reported outcome (PRO) domains between three arthritis phenotypes [undifferentiated arthritis (UA),…”
Get full text

Correction to: The impact of different (rheumatoid) arthritis phenotypes on patients’ lives by Luurssen-Masurel, Nathalie, Weel, Angelique Elisabeth Adriana Maria, Hazes, Johanna Maria Wilhelmina, de Jong, Pascal Hendrik Pieter

Get full text

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients by Luurssen-Masurel, Nathalie, Van Mulligen, Elise, Weel, Angelique Elisabeth Adriana Maria, Hazes, Johanna Maria Wilhelmina, de Jong, Pascal Hendrik Pieter

Get full text

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients by Nathalie, Luurssen-Masurel, Mulligen, Van Elise, Maria, Weel Angelique Elisabeth Adriana, Wilhelmina, Hazes Johanna Maria, Pieter, de Jong Pascal Hendrik

“…Abstract Objectives To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative RA patients,…”
Get full text

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial by de Jong, P H, Hazes, J M, Barendregt, P J, Huisman, M, van Zeben, D, van der Lubbe, P A, Gerards, A H, de Jager, M H, de Sonnaville, P B, Grillet, B A, Luime, J J, Weel, A E

“…To determine the most effective induction disease-modifying antirheumatic drug (DMARD) strategy in early rheumatoid arthritis (RA), second to compare one…”
Get more information

The likelihood of attaining and maintaining DMARD-free remission for various (rheumatoid) arthritis phenotypes by Luurssen-Masurel, Nathalie, van Mulligen, Elise, Weel-Koenders, Angelique Elisabeth Adriana Maria, Hazes, Johanna Maria Wilhelmina, de Jong, Pascal Hendrik Pieter, Aartsen, R C, Alfenaar, C, Alves, R, Arendse, M, Arnoldus, M, Baak-Dijkstra, J, Bal-overzier, P, Barendregt, N, Basoski, S, Beer, D, Berkel, F, Bonte, M, Born van den, D, Breukelen van, S, Bron, H, Buijs, N, Buijs, M, Cambier, D, Cateten, S, Claessen, E, Colin, A, Dekker, R, Dolhain, M, Donze, F, Fodili, A, Gerards, G, Goudeketting, B, Grillet de, H, Haasnoot, B, Hamelink, K, Han, J, Hazes, Y, Houdt van, L, Hove van, M, Huisman, J, Jager de, M, Jager de, J, Jasperse, C, Jonkers, S, Joziasse, C, Kaal-Alfenaar, K, Klootwijk, T, Krommenhoek, M, Krugten van, T, Kuijper, W, Lam Tse, H, Leemput van, C, Legierse, M, Lenssinck, P, Lubbe van de, P, Maclean, Y, Man de, D, Matena, A, Molenaar, L, Mous, J, Nijs, H, Paassen van, R, Quax, J, Reijnierse, A, Romme, M, Rotte de, M, Saltzherr, B, Schaeybroeck, G, Schardijn, S, Schrauwen, P, Sonnaville de, F, Steenwinkel de, L, Sturm, T, Sutter, I, Tchetverikov, D, Tusschenbroek, R, Veldman, M, Vis, A, Voordt van der, H, Voorneveld, M, Vroed de, M, Walravens, M, Walter, A, Weel, N, Werff van de, A, Westeinde van het, J, Wiele, M, Willemse, J, Wouter, W, Zandbergen, D, Zeben van, H, Zwart

“…Abstract Objectives The objective of this study was to compare DMARD-free remission rates (DFRs) and sustained DFRs (SDFRs), defined as, respectively, DFR for…”
Get full text

The susceptibility of attaining and maintaining DMARD-free remission in different (rheumatoid) arthritis phenotypes by Luurssen-Masurel, Nathalie, van Mulligen, Elise, Weel-Koenders, Angelique Elisabeth Adriana Maria, Hazes, Johanna Maria Wilhelmina, de Jong, Pascal Hendrik Pieter

“…To compare (sustained) DMARD-free remission rates((S)DFR), defined as respectively ≥6 months and >1 year, after 2 and 5 years between three clinical arthritis…”
Get full text

Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study by de Jong, Pascal Hendrik Pieter, Quax, Rogier A, Huisman, Margriet, Gerards, A H, Feelders, Richard A, de Sonnaville, Peter B, Luime, Jolanda J, Weel, Angelique E, Hazes, J M

“…To investigate if a glucocorticoid (GC) response at 2 weeks, defined by EULAR response criteria, can predict active disease (Disease Activity Score (DAS)>2.4)…”
Get more information